Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — November 2013

Planlagt Fastgjort Låst Flyttet Genmab
226 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • JørgenVarnæsJ Offline
    JørgenVarnæsJ Offline
    JørgenVarnæs
    wrote on sidst redigeret af
    #201

    er HSBC's opkøbsforsøg gået i sig selv igen?

    1 Reply Last reply
    0
    • investor1989I Offline
      investor1989I Offline
      investor1989
      wrote on sidst redigeret af
      #202

      http://www.proinvestor.com/index.php?p=debat_post&postid=67169

      1 Reply Last reply
      0
      • S Offline
        S Offline
        stoft
        wrote on sidst redigeret af
        #203

        Det blir dejlig af være genmab aktionær idag 🙂

        1 Reply Last reply
        0
        • JørgenVarnæsJ Offline
          JørgenVarnæsJ Offline
          JørgenVarnæs
          wrote on sidst redigeret af
          #204

          Der bliver varmet om til ASH og det store showdown i CLL markedet - her er lidt baggrund på de forskellige spillere: http://seekingalpha.com/article/1860201-gilead-vs-johnson-johnson-roche-in-blood-cancer-showdown?source=yahoo

          1 Reply Last reply
          0
          • MadsSkjernM Offline
            MadsSkjernM Offline
            MadsSkjern
            wrote on sidst redigeret af
            #205

            CLL, competitive landscape. Arzerra er godt med i kombi med ibrutinib og idelalisib https://twitter.com/zDonShimoda/status/405007
            519640064000/photo/1/large

            1 Reply Last reply
            0
            • MadsSkjernM Offline
              MadsSkjernM Offline
              MadsSkjern
              wrote on sidst redigeret af
              #206

              https://twitter.com/zDonShimoda/status/405007519640064000/photo/1/large

              1 Reply Last reply
              0
              • JørgenVarnæsJ Offline
                JørgenVarnæsJ Offline
                JørgenVarnæs
                wrote on sidst redigeret af
                #207

                ja, det bliver lidt af et landskab at fylde ud. Arzerra + alkylator er ikke taget med i opgørelsen.

                1 Reply Last reply
                0
                • investor1989I Offline
                  investor1989I Offline
                  investor1989
                  wrote on sidst redigeret af
                  #208

                  "
                  This has made some investors nervous. Michael Yee of RBC Capital Markets speculates that the FDA is waiting for data from the ongoing Resonate trial in January which compares Imbruvica to Arzerra, a drug made by GlaxoSmithKline (GSK)."

                  1 Reply Last reply
                  0
                  • investor1989I Offline
                    investor1989I Offline
                    investor1989
                    wrote on sidst redigeret af
                    #209

                    Var faktisk ikke klar over at vi fik sådanne data

                    1 Reply Last reply
                    0
                    • investor1989I Offline
                      investor1989I Offline
                      investor1989
                      wrote on sidst redigeret af
                      #210

                      Gazyva comes with a boxed warning about the possibility that the Hepatitis B virus could reactivate and it could cause PML (progressive multifocal leukoencephalopathy). PML is a rare brain disorder that damages the material which protects the nerves in the brain.

                      1 Reply Last reply
                      0
                      • investor1989I Offline
                        investor1989I Offline
                        investor1989
                        wrote on sidst redigeret af
                        #211

                        lyder hyggeligt 🙂

                        1 Reply Last reply
                        0
                        • G Offline
                          G Offline
                          gentogen
                          wrote on sidst redigeret af
                          #212

                          BendOfa refractory CLL: The overall response rate (ORR), as per intention-to-treat analysis, was 72.3% (95% CI, 57–84%), with 17% complete responses. After a median follow-up of 24.2 months, the overall survival was 83.6% (95% CI, 73.0–95.7%) and the progression-free survival (PFS) 49.6% (95% CI, 35.9–68.6%). The median PFS was 23.6 months.

                          1 Reply Last reply
                          0
                          • G Offline
                            G Offline
                            gentogen
                            wrote on sidst redigeret af
                            #213

                            BendOfa is feasible and effective in relapsed/refractory CLL patients, including patients with high risk clinical and biological features.

                            1 Reply Last reply
                            0
                            • G Offline
                              G Offline
                              gentogen
                              wrote on sidst redigeret af
                              #214

                              accepted article preview 13 November 2013; doi: 10.1038/leu.2013.334 http://www.nature.com/leu/journal/vaop/naam/abs/leu2013334a.html

                              1 Reply Last reply
                              0
                              • JørgenVarnæsJ Offline
                                JørgenVarnæsJ Offline
                                JørgenVarnæs
                                wrote on sidst redigeret af
                                #215

                                Ja - arzerra er ikke helt uden virkning

                                1 Reply Last reply
                                0
                                • celsiusC Offline
                                  celsiusC Offline
                                  celsius
                                  wrote on sidst redigeret af
                                  #216

                                  Gentogen: og så på dansk -:)

                                  1 Reply Last reply
                                  0
                                  • celsiusC Offline
                                    celsiusC Offline
                                    celsius
                                    wrote on sidst redigeret af
                                    #217

                                    Gentogen: jeg er bare ein dumme dänen -:)

                                    1 Reply Last reply
                                    0
                                    • SolsenS Offline
                                      SolsenS Offline
                                      Solsen
                                      wrote on sidst redigeret af
                                      #218

                                      Det er jo resultater på linie med frontline - ganske pænt i refrac !!!

                                      1 Reply Last reply
                                      0
                                      • JørgenVarnæsJ Offline
                                        JørgenVarnæsJ Offline
                                        JørgenVarnæs
                                        wrote on sidst redigeret af
                                        #219

                                        det eneste problem med de resultater er efterhånden, at CR er lidt for høj....

                                        1 Reply Last reply
                                        0
                                        • JørgenVarnæsJ Offline
                                          JørgenVarnæsJ Offline
                                          JørgenVarnæs
                                          wrote on sidst redigeret af
                                          #220

                                          vi fik vist ikke markeret denne - http://seekingalpha.com/currents/post/1410482 det er btd kandidat nr 2, der bliver godkendt

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger